Pfizer Recalls Replax for Possible Contamination

Pfizer recalled two lots of its migraine treatment Replax (eletriptan hydrobromide) for potential bacterial contamination.

The lots “may not meet Pfizer’s in-house microbiological specifications for Pseudomonas and Burkholderia,” the company said.

The bacteria could lead to serious adverse events in vulnerable patients such as those with compromised immune systems, cystic fibrosis and chronic granulomatous disease. Pfizer said it did not receive any reports of adverse events related to the issue.